NASDAQ:FPRX

Five Prime Therapeutics Competitors

$37.94
+0.05 (+0.13 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$37.90
Now: $37.94
$37.96
50-Day Range
$21.26
MA: $33.67
$38.00
52-Week Range
$2.61
Now: $37.94
$38.90
Volume653,247 shs
Average Volume2.05 million shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.4

Competitors

Five Prime Therapeutics (NASDAQ:FPRX) Vs. RARE, GWPH, ASND, ARWR, TGTX, and IONS

Should you be buying FPRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Five Prime Therapeutics, including Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Five Prime Therapeutics (NASDAQ:FPRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Five Prime Therapeutics and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Insider and Institutional Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Five Prime Therapeutics and Ultragenyx Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million118.83$-137,200,000.00($3.92)-9.68
Ultragenyx Pharmaceutical$103.71 million66.80$-402,730,000.00($7.36)-14.06

Five Prime Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Five Prime Therapeutics has a beta of 4.4, indicating that its share price is 340% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Five Prime Therapeutics and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Ultragenyx Pharmaceutical06802.57

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, suggesting a potential upside of 26.79%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Five Prime Therapeutics.

Summary

Ultragenyx Pharmaceutical beats Five Prime Therapeutics on 8 of the 14 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Five Prime Therapeutics and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Institutional and Insider Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Five Prime Therapeutics and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million118.83$-137,200,000.00($3.92)-9.68
GW Pharmaceuticals$311.33 million21.94$-9,020,000.00($0.24)-908.04

GW Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Five Prime Therapeutics and GW Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
GW Pharmaceuticals010402.29

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.35%. Given GW Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe GW Pharmaceuticals is more favorable than Five Prime Therapeutics.

Summary

GW Pharmaceuticals beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Five Prime Therapeutics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Institutional and Insider Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Five Prime Therapeutics and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million118.83$-137,200,000.00($3.92)-9.68
Ascendis Pharma A/S$14.98 million450.70$-244,180,000.00($5.25)-23.93

Five Prime Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Five Prime Therapeutics and Ascendis Pharma A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Ascendis Pharma A/S011102.92

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 49.40%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Institutional and Insider Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Five Prime Therapeutics and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Arrowhead Pharmaceuticals021002.83

Five Prime Therapeutics presently has a consensus target price of $30.7143, suggesting a potential downside of 19.05%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, suggesting a potential upside of 37.26%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Five Prime Therapeutics.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Profitability

This table compares Five Prime Therapeutics and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Valuation and Earnings

This table compares Five Prime Therapeutics and Arrowhead Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million118.83$-137,200,000.00($3.92)-9.68
Arrowhead Pharmaceuticals$87.99 million73.31$-84,550,000.00($0.84)-73.99

Arrowhead Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arrowhead Pharmaceuticals beats Five Prime Therapeutics on 9 of the 14 factors compared between the two stocks.

TG Therapeutics (NASDAQ:TGTX) and Five Prime Therapeutics (NASDAQ:FPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

65.7% of TG Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 13.2% of TG Therapeutics shares are held by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for TG Therapeutics and Five Prime Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TG Therapeutics00503.00
Five Prime Therapeutics06202.25

TG Therapeutics currently has a consensus price target of $64.00, suggesting a potential upside of 42.89%. Five Prime Therapeutics has a consensus price target of $30.7143, suggesting a potential downside of 19.05%. Given TG Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe TG Therapeutics is more favorable than Five Prime Therapeutics.

Risk and Volatility

TG Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500.

Profitability

This table compares TG Therapeutics and Five Prime Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TG Therapeutics-151,798.69%-223.96%-108.08%
Five Prime Therapeutics-554.71%-75.84%-49.08%

Valuation & Earnings

This table compares TG Therapeutics and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$150,000.0041,978.98$-172,870,000.00($1.83)-24.48
Five Prime Therapeutics$14.87 million118.83$-137,200,000.00($3.92)-9.68

Five Prime Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Five Prime Therapeutics beats TG Therapeutics on 8 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and Five Prime Therapeutics (NASDAQ:FPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Ionis Pharmaceuticals and Five Prime Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals27602.27
Five Prime Therapeutics06202.25

Ionis Pharmaceuticals currently has a consensus price target of $57.9091, suggesting a potential upside of 36.71%. Five Prime Therapeutics has a consensus price target of $30.7143, suggesting a potential downside of 19.05%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Five Prime Therapeutics.

Risk and Volatility

Ionis Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500.

Profitability

This table compares Ionis Pharmaceuticals and Five Prime Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
Five Prime Therapeutics-554.71%-75.84%-49.08%

Valuation & Earnings

This table compares Ionis Pharmaceuticals and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion5.31$303.26 million$2.0820.37
Five Prime Therapeutics$14.87 million118.83$-137,200,000.00($3.92)-9.68

Ionis Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Ionis Pharmaceuticals beats Five Prime Therapeutics on 11 of the 14 factors compared between the two stocks.

Ad Legacy Research
Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video)
"Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project… What happens next will shock you…"

Five Prime Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.48+3.0%$6.93 billion$103.71 million-23.57News Coverage
Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.93+0.0%$6.83 billion$311.33 million-126.70Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.61+3.1%$6.75 billion$14.98 million-15.30Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.15+2.5%$6.45 billion$87.99 million-73.99News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.79+4.3%$6.30 billion$150,000.00-21.13Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36+0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54+1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00+2.9%$5.58 billionN/A-38.32Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16+0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53+0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90+4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81+0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51+0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61+0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39+2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24+2.3%$4.26 billion$204.89 million-36.55News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35+1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29+0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95+3.9%$3.87 billionN/A-22.49Analyst Report
LEGN
Legend Biotech
1.2$28.45+6.5%$3.76 billion$64.39 million0.00
I-Mab logo
IMAB
I-Mab
1.4$51.65+2.3%$3.72 billion$4.31 million-1.79
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77+0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41+0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63+3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60+1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56+0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70+2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39+1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42+7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91+0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49+1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02+0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36+0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84+4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18+2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83+0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69+0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77+13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44+1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77+1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81+1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41+8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19+0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29+3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47+2.9%$2.35 billion$156.70 million-28.91News Coverage
Amarin logo
AMRN
Amarin
1.6$5.93+1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30+1.3%$2.22 billion$15 million-16.39
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.